Lucid Diagnostics Inc.
LUCD evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for LUCD—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · LUCD
Lucid Diagnostics Inc. is a commercial-stage diagnostics company focused on the EsoGuard Esophageal DNA Test for early detection of esophageal precancer and cancer, currently pursuing multi-channel commercialization and insurance reimbursement.
Key risk: Reimbursement dependency
BioSniper Score
Based on 4 of 6 signals
Market Cap
$189.3M
Cash Runway
—
Lead Asset
esoguard (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 6 clinical trials for Lucid Diagnostics Inc..
Similar companies
Lucid Diagnostics Inc. is a commercial-stage diagnostics company focused on the EsoGuard Esophageal DNA Test for early detection of esophageal precancer and cancer, currently pursuing multi-channel commercialization and insurance reimbursement.
- Total revenue of $1.5M and net loss of -$11.7M for the period ended 2026-06-30 [sec].
- Shareholders' equity of $10.9M as of 2026-06-30 [sec].
- Operational activities are principally focused on the commercialization of EsoGuard across multiple sales channels [sec_mda · as of 2026-08-12].
- The company is developing expanded clinical evidence to support insurance reimbursement adoption by government and private insurers [sec_mda · as of 2026-08-12].
- Lucid Diagnostics has a limited operating history and has incurred significant losses to date [sec_mda · as of 2025-11-12].
What works
- The company is actively pursuing commercialization across multiple sales channels, including Lucid Test Centers, mobile testing units, and direct contracting with self-insured employers [sec_mda · as of 2026-08-12].
- Lucid Diagnostics is developing expanded clinical evidence to support insurance reimbursement adoption, which could drive revenue growth [sec_mda · as of 2026-08-12].
What to weigh
- The company's ability to continue operations depends on generating substantial revenue conditioned on obtaining positive third-party reimbursement coverage [sec_mda · as of 2026-05-13].
- Lucid Diagnostics has a limited operating history and has incurred significant losses, with a net loss of -$11.7M for the period ended 2026-06-30 [sec].
- The company will need to raise additional capital through debt or equity financing to fund operations, as it has not yet achieved positive cash flow from operations [sec_mda · as of 2026-05-13].
From the filings
Quoted directly from source documents.
The company's primary focus is commercializing EsoGuard.
“Our current operational activities are principally focused on the commercialization of EsoGuard.”
SEC MD&A · August 12, 2026
The company is pursuing multiple sales channels.
“We are pursuing commercialization across multiple sales channels, including: the communication to and education of medical practitioners and clinicians regarding EsoGuard; the establishment of Lucid Test Centers for the collection of cell samples using EsoCheck; use of our mobile testing unit; ongoing #CheckYourFoodTube testing days; and our direct contracting strategic initiative (including in the concierge medicine and employer markets sectors).”
SEC MD&A · August 12, 2026
The company's ability to continue operations depends on obtaining positive third-party reimbursement.
“The Company's ability to continue operations 12 months beyond the issuance of the financial statements will depend upon generating substantial revenue that is conditioned on obtaining positive third-party reimbursement coverage for its EsoGuard Esophageal DNA Test from both government and private health insurance providers”
SEC MD&A · May 13, 2026
Risks & what to watch (4)›
Key risks
- Reimbursement dependency — Revenue growth hinges on obtaining positive third-party reimbursement coverage from government and private insurers [sec_mda · as of 2026-05-13].
- Going concern risk — Company may need additional capital to fund operations beyond 12 months if revenue and financing are insufficient [sec_mda · as of 2026-05-13].
- Limited operating history — Lucid Diagnostics has a limited operating history and has incurred significant losses, with no assurance of future profitability [sec_mda · as of 2025-11-12].
- Regulatory and commercial uncertainty — Ability to obtain regulatory approval and successfully commercialize products is uncertain [sec_mda · as of 2025-11-12].
What to watch
- Progress in obtaining positive reimbursement decisions from government and private insurers [sec_mda · as of 2026-08-12].
- Revenue growth trajectory and ability to reduce net losses [sec].
- Any equity or debt financing activities to extend cash runway [sec_mda · as of 2026-05-13].
- Expansion of clinical evidence supporting EsoGuard and its impact on adoption [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 29, 2026 · How we verify sources →
Run Lucid Diagnostics Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Lucid Diagnostics Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.56
Lead: Approved
1 candidate
No upcoming catalysts tracked
1 buy · 0 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
100
Total value held
$39.6M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 8,309,540 | $9.6M |
| blackrock, inc. | 4,638,243 | $5.3M |
| masters capital management llc | 4,000,000 | $4.6M |
| two seas capital lp | 3,000,000 | $3.5M |
| geode capital management, llc | 2,245,350 | $2.6M |
| state street corp | 1,554,581 | $1.8M |
| wells fargo & company/mn | 1,274,390 | $1.5M |
| perkins capital management inc | 1,126,000 | $1.3M |
| sunbelt securities, inc. | 900,013 | $1.0M |
| northern trust corp | 670,585 | $771K |
Showing top 10 of 100 institutional holders of Lucid Diagnostics Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 11, 2026- % of float
- 4.7%
- Days to cover
- 9.7
- Shares short
- 6,228,117
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
LUCD short interestGovernance
Frequently asked questions
What is the AI investment thesis for Lucid Diagnostics Inc.?
Lucid Diagnostics Inc. is a commercial-stage diagnostics company focused on the EsoGuard Esophageal DNA Test for early detection of esophageal precancer and cancer, currently pursuing multi-channel commercialization and insurance reimbursement.
What is Lucid Diagnostics Inc.'s lead drug candidate?
Lucid Diagnostics Inc.'s most advanced tracked candidate is esoguard (Approved) for Barrett's Esophagus (BE) and esophageal adenocarcinoma (EAC).
Who is the CEO of Lucid Diagnostics Inc.?
Dr. Lishan Aklog M.D. is the chief executive officer of Lucid Diagnostics Inc. (LUCD).
Where is Lucid Diagnostics Inc. headquartered?
Lucid Diagnostics Inc. (LUCD) is headquartered in New York, NY, United States.
What therapeutic areas does Lucid Diagnostics Inc. focus on?
Lucid Diagnostics Inc. develops therapies across Oncology, Rare Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.